Jump to content

Oxprenolol

From Wikipedia, the free encyclopedia
(Redirected from Trasicor)
Oxprenolol
Clinical data
Trade namesTrasicor, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20–70%
MetabolismLiver
Elimination half-life1–2 hours
ExcretionKidney
Lactic (in lactiferous females)
Identifiers
  • (RS)-1-[2-(allyloxy)phenoxy]-3-(isopropylamino)propan-2-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.026.598 Edit this at Wikidata
Chemical and physical data
FormulaC15H23NO3
Molar mass265.353 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O(c1ccccc1OC\C=C)CC(O)CNC(C)C
  • InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3 checkY
  • Key:CEMAWMOMDPGJMB-UHFFFAOYSA-N checkY
  (verify)

Oxprenolol, sold under the brand name Trasicor among others, is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms, and high blood pressure.

Medical uses

[edit]

Oxprenolol is used in the treatment of angina pectoris, abnormal heart rhythms, and high blood pressure.

It has been used to treat anxiety as well.[1][2]

Contraindications

[edit]

Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.[3]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Oxprenolol is a beta blocker. In addition, it has been found to act as an antagonist of the serotonin 5-HT1A and 5-HT1B receptors with respective Ki values of 94.2 nM and 642 nM in rat brain tissue.[4]

Pharmacokinetics

[edit]

Oxprenolol is a lipophilic beta blocker which passes the blood–brain barrier more easily than hydrophilic beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than beta blockers with more hydrophilic molecules such as atenolol, sotalol, and nadolol.[5] The brain-to-blood ratio of oxprenolol in humans has been found to be 50:1.[6] For comparison, the brain-to-blood ratio of the highly lipophilic propranolol was 15:1 to 26:1 and of the hydrophilic atenolol was 0.2:1.[6]

Chemistry

[edit]

The experimental log P of oxprenolol is 2.10.[7][8]

Stereochemistry

[edit]

Oxprenolol is a chiral compound, the beta blocker is used as a racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.[9]

(R)-(+)-Oxprenolol (top) and (S)-(–)-oxprenolol

Society and culture

[edit]

Brand names

[edit]

Brand names of oxprenolol include Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, and Trasidex.

References

[edit]
  1. ^ Boyce TG, Ballone NT, Certa KM, Becker MA (2021). "The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review". J Acad Consult Liaison Psychiatry. 62 (4): 404–412. doi:10.1016/j.jaclp.2020.12.009. PMID 34210401.
  2. ^ Archer C, Wiles N, Kessler D, Turner K, Caldwell DM (January 2025). "Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis". J Affect Disord. 368: 90–99. doi:10.1016/j.jad.2024.09.068. PMID 39271062.
  3. ^ Williams IP, Millard FJ (February 1980). "Severe asthma after inadvertent ingestion of oxprenolol". Thorax. 35 (2): 160. doi:10.1136/thx.35.2.160. PMC 471246. PMID 7376124.
  4. ^ Langlois M, Brémont B, Rousselle D, Gaudy F (January 1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 244 (1): 77–87. doi:10.1016/0922-4106(93)90061-d. PMID 8093601.
  5. ^ McDevitt DG (December 1987). "Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs". European Heart Journal. 8. 8 Suppl M: 9–14. doi:10.1093/eurheartj/8.suppl_M.9. PMID 2897304.
  6. ^ a b Drayer DE (1987). "Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers". Pharmacotherapy. 7 (4): 87–91. doi:10.1002/j.1875-9114.1987.tb04029.x. PMID 2891122.
  7. ^ https://pubchem.ncbi.nlm.nih.gov/compound/4631
  8. ^ https://go.drugbank.com/drugs/DB01580
  9. ^ Abounassif MA, Hefnawy MM, Mostafa GA (2011). "Separation and quantitation of oxprenolol in urine and pharmaceutical formulations by HPLC using a Chiralpak IC and UV detection". Monatshefte für Chemie - Chemical Monthly. 143 (3): 365–371. doi:10.1007/s00706-011-0605-4. S2CID 95959906.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Oxprenolol&oldid=1299868689"